Lymphogranuloma Venereum Treatment and Prognosis

Lymphogranuloma venereum represents a sexually-transmitted disease caused by specific serovars L1-3 of the obligate intracellular bacterium Chlamydia trachomatis.

The disease presents with a shallow ulcer or painless papule, and enlarged and tender lymph nodes (known as buboes) arise in the regional lymphatics. Lymphogranuloma venereum is also an important cause of proctitis in men who have sex with men.

It is important to rule out other potential causes of genital ulceration and inguinal lymphadenopathy before any therapeutic interventions. Early medical treatment is of immense value for preventing disease transmission, as well as for halting the development of complications and potentially mutilating sequelae.

Treatment Algorithm

The goal of therapy for lymphogranuloma venereum is to eradicate the putative microorganism. The treatment of choice (supported by more than fifty years of clinical experience) is doxycycline, 100 milligrams two times per day for a total of 21 days. This recommendation is based on numerous case series, and the regimen is characterized by convenient dosage, minimal toxicity and favorable pharmacokinetic profile.

The alternative approach is erythromycin base, 500 milligrams four times per day for a total of 21 days. The proposed three-week period in both instances is necessary since lymphogranuloma venereum is more invasive and problematic to eradicate when compared to uncomplicated infections of the genital tract. Treatments based on fluoroquinolones might also be effective, but there are no studies evaluating the optimal duration of treatment.

The activity of azithromycin against Chlamydia trachomatis suggests that this drug may also be effective, but at the moment we lack supporting clinical data. It is being used as a medication for pregnant women, although official recommendations still endorse erythromycin stearate regimen.

In addition to antibiotics, local management of buboes (primarily by incision and drainage, or by aspiration through intact skin) must be considered in order to prevent the development of fistulous tracts. Rectal strictures should be dilated at weekly intervals – either manually or with elastic bougies.

Follow-up and Prognosis

Patients should be monitored until symptoms and signs of the disease have resolved, which may occur within 3-6 weeks. Tests of cure should be performed approximately 3-4 weeks after effective treatment is completed in order to avoid false positive findings due to the presence of non-viable microorganisms (especially if molecular methods are used).

In any case, prognosis is excellent for acute infections that are treated with appropriate antimicrobial drugs. In instances of anatomical defects that may necessitate surgical interventions (such as strictures, sinus or fistulae), patients need to be followed up until their problem is resolved.

Partner management is also pivotal; individuals who have had sexual contacts with the affected patient within six months of the symptom appearance, or in instances of asymptomatic disease at the time of diagnosis, should be adequately examined, tested for Chlamydia trachomatis, and treated empirically immediately.

Prevention Efforts

In endemic areas of the world, lymphogranuloma venereum can be successfully prevented by avoiding casual sexual contact (particularly with commercial sex workers) and by practicing safe sexual habits (most notably by using condoms). As already mentioned, all sexual contacts must be traced and swiftly treated.

The use of enema prior to receptive anal intercourse should be discouraged, as it is linked to rectal chlamydial infections, and especially lymphogranuloma venereum proctitis. Health-seeking behavior and health literacy of those at risk must be encouraged.

In conclusion, there is a need for cheaper and improved screening tools if we are to detect cases in larger groups of people at risk. This is of utmost importance to prevent potential complications and stop transmission in the community. A deeper understanding of both microbial and immunological background of lymphogranuloma venereum will aid in successfully tackling this infection.


  7. de Vries HJC, Reddy BSN, Khandpur S. Lymphogranuloma Venereum. In: Kumar B, Gupta S, editors. Sexually Transmitted Infections, Second Edition. Elsevier Health Sciences, 2014; pp. 506-521.

Further Reading

Last Updated: Dec 29, 2022

Dr. Tomislav Meštrović

Written by

Dr. Tomislav Meštrović

Dr. Tomislav Meštrović is a medical doctor (MD) with a Ph.D. in biomedical and health sciences, specialist in the field of clinical microbiology, and an Assistant Professor at Croatia's youngest university - University North. In addition to his interest in clinical, research and lecturing activities, his immense passion for medical writing and scientific communication goes back to his student days. He enjoys contributing back to the community. In his spare time, Tomislav is a movie buff and an avid traveler.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Meštrović, Tomislav. (2022, December 29). Lymphogranuloma Venereum Treatment and Prognosis. News-Medical. Retrieved on July 24, 2024 from

  • MLA

    Meštrović, Tomislav. "Lymphogranuloma Venereum Treatment and Prognosis". News-Medical. 24 July 2024. <>.

  • Chicago

    Meštrović, Tomislav. "Lymphogranuloma Venereum Treatment and Prognosis". News-Medical. (accessed July 24, 2024).

  • Harvard

    Meštrović, Tomislav. 2022. Lymphogranuloma Venereum Treatment and Prognosis. News-Medical, viewed 24 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.